Lyumjev (Insulin Lispro-aabc) Injection shortage
Possibly permanent — Eli Lilly, the only company we could find that sells insulin lispro-aabc injections, has told the FDA it is discontinuing its product as of Oct 8, 2026. The FDA lists this under “To be discontinued”. We could not find another company that sells the same medicine, so talk with your prescriber about a long-term plan before your supply runs out.
Eli Lilly is permanently discontinuing Lyumjev (insulin lispro-aabc) injection. No other manufacturer makes this medicine, so it will not be available from any source once supplies run out.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Lyumjev still in shortage? — status as of Oct 8, 2026
Still listed as “To be discontinued” as of Oct 8, 2026. We could not find another company that sells insulin lispro-aabc injections, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; we could not confirm another company listing it (see below).
Shortage timeline
-
Oct 24, 2025Currently in shortage2 of 2 products affected.
-
Oct 24, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Lyumjev products are affected — by company
Company: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Lyumjev Injection | U-100 Tempo Pen | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Lyumjev Injection | U-100 Tempo Pen Sample | — | A business decision was made to discontinue manufacture of the drug. | — |
These rows are company reports to the FDA for Insulin Lispro-aabc Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock.
Why is Eli Lilly discontinuing Lyumjev?
Eli Lilly has made a business decision to permanently stop making two specific versions of Lyumjev (insulin lispro-aabc): the U-100 Tempo Pen and the U-100 Tempo Pen Sample. No specific reason beyond it being a business decision was shared publicly — the manufacturer did not give a more detailed explanation.
It's worth knowing that this report covers only these two Tempo Pen presentations from Eli Lilly. Other forms or strengths of Lyumjev are not mentioned in this report, so this discontinuation applies specifically to those Tempo Pen packages, not necessarily every version of this insulin.
Based on the company-reported reason(s) and notes on file with the FDA for Insulin Lispro-aabc Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Lyumjev?
Insulin lispro-aabc injection (also sold as Lyumjev) is currently on the FDA shortage list, and the status for this record is listed as "to be discontinued."
The product affected here is the U-100 Tempo Pen from Eli Lilly and Co., including the sample version. The reported reason is a business decision by the manufacturer to discontinue making the drug. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for this particular product, so planning ahead with your care team is the right next step.
Here is what I suggest:
- Do not stop, skip, or change your doses on your own — keep taking your insulin as prescribed while you sort out supply.
- Ask your pharmacy to check wholesalers and other manufacturers; a pharmacy can often locate stock that isn't visible from national reports.
- If your pen can no longer be found, talk with your prescriber or pharmacist about options, such as a clinician-chosen alternative insulin that fits your needs.
- The manufacturer's contact number is listed on this page for reference, though your pharmacy usually handles those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock, so please confirm with them.
- Ask your pharmacy to check other companies’ versions, other strengths / sizes, package sizes, and nearby stores.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 5 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| LYUMJEV Tempo Pen 100 [iU]/mL | Eli | 5 syringes | $10.138 | — | Availability likely |
| LYUMJEV KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.155 | — | Availability likely |
| Lyumjev 100 [iU]/mL | Eli | 5 cartridges | — | — | FDA listed |
| LYUMJEV Junior KwikPen 100 [iU]/mL | Eli | 5 syringes | — | — | FDA listed |
| LYUMJEV Tempo Pen 100 [iU]/mL | Eli | 1 syringe | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Lyumjev — that fall in the same broad treatment class (insulins) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other endocrinology/metabolism shortages
Lyumjev shortage FAQs
Is Lyumjev still in shortage?
Which Lyumjev products are affected?
When will Lyumjev be available again?
Is the brand or the generic affected?
What should I do if I take Lyumjev?
Still have a question about the Lyumjev shortage?
Ask a pharmacist about this shortage →View Insulin Lispro-Aabc Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.